Evidence map›Paper›PMID 27090176›Full record

ArticleAntimicrobial agents and chemotherapy2016

Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.

S B Georghiou, M Seifert, D Catanzaro, R S Garfein, F Valafar, V Crudu, C Rodrigues, T C Victor, A Catanzaro, T C Rodwell

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02170441 (Global Consortium for Drug-resistant Tuberculosis Diagnostics), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02170441 completednot on this map

Global Consortium for Drug-resistant Tuberculosis Diagnostics

TypeobservationalSponsorUniversity of California, San DiegoRan2012 to 2014Enrolled1,128ConditionsTuberculosis, Tuberculosis, Multidrug-Resistant
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Tale of compounding oddities.BMJ case reports · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Genotypicdiversity of drug-resistantInternational journal of clinical and experimental pathology · 2018
    Article
  14. Article
  15. Article
  16. Observational
  17. Isoniazid-resistant tuberculosis: a cause for concern?The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2017
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

S B GeorghiouDepartment of Medicine, University of California, San Diego, La Jolla, California, USA sgeorghi@ucsd.edu.
M SeifertDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
D CatanzaroUniversity of Arkansas, Fayetteville, Arkansas, USA.
R S GarfeinDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
F ValafarBiological and Medical Informatics Research Center, San Diego State University, San Diego, California, USA.
V CruduMicrobiology and Morphology Laboratory, Institute of Phthisiopneumology, Chisinau, Moldova.
C RodriguesDepartment of Microbiology, P. D. Hinduja Hospital and Medical Research Centre, Mumbai, India.
T C VictorDivision of Molecular Biology and Human Genetics, Stellenbosch University, Stellenbosch, South Africa.
A CatanzaroDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
T C RodwellDepartment of Medicine, University of California, San Diego, La Jolla, California, USA.
University of California, San Diego · USP. D. Hinduja Hospital and Medical Research Centre · INPhthisiopneumology Institute "Chiril Draganiuc" · MDSan Diego State University · USStellenbosch University · ZAUniversity of Arkansas at Fayetteville · US

Funding

Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant TuberculosisU01AI082229 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CATANZARO, ANTONINO · 2009 to 2013
$10.9M
An Integrated Tabletop Platform for Rapid Detection of XDR-TB in Clinical SamplesR01AI111435 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RODWELL, TIMOTHY CHARLES · 2014 to 2018
$5.4M
Evolutionary and Functional Significance of Novel Mutations in MDR-XDR TBR01AI105185 · NIAID · SAN DIEGO STATE UNIVERSITY · PI VALAFAR, FARAMARZ · 2013 to 2021
$5.3M
Training in the Next Generation in Respiratory ScienceT32HL134632 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALHOTRA, ATUL, POWELL, FRANK L. · 2017 to 2021
$2.1M
Training in Respiratory Biology: Innovate, Integrate, and TranslateT32HL098062 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI POWELL, FRANK L. · 2010 to 2014
$2.1M
NHLBI NIH HHS T32 HL098062NHLBI NIH HHS T32 HL134632NIAID NIH HHS R01 AI105185NIAID NIH HHS R01 AI111435NIAID NIH HHS U01 AI082229
6 · The paper itself

Abstract

Molecular diagnostic assays, with their ability to rapidly detect resistance-associated mutations in bacterial genes, are promising technologies to control the spread of drug-resistant tuberculosis (DR-TB). Sequencing assays provide detailed information for specific gene regions and can help diagnostic assay developers prioritize mutations for inclusion in their assays. We performed pyrosequencing of seven Mycobacterium tuberculosis gene regions (katG, inhA, ahpC, rpoB, gyrA, rrs, and eis) for 1,128 clinical specimens from India, Moldova, and South Africa. We determined the frequencies of each mutation among drug-resistant and -susceptible specimens based on phenotypic drug susceptibility testing results and examined mutation distributions by country. The most common mutation among isoniazid-resistant (INH(r)) specimens was the katG 315ACC mutation (87%). However, in the Eastern Cape, INH(r) specimens had a lower frequency of katG mutations (44%) and higher frequencies of inhA (47%) and ahpC (10%) promoter mutations. The most common mutation among rifampin-resistant (RIF(r)) specimens was the rpoB 531TTG mutation (80%). The mutation was common in RIF(r) specimens in Mumbai (83%) and Moldova (84%) but not the Eastern Cape (17%), where the 516GTC mutation appeared more frequently (57%). The most common mutation among fluoroquinolone-resistant specimens was the gyrA 94GGC mutation (44%). The rrs 1401G mutation was found in 84%, 84%, and 50% of amikacin-resistant, capreomycin-resistant, and kanamycin (KAN)-resistant (KAN(r)) specimens, respectively. The eis promoter mutation -12T was found in 26% of KAN(r) and 4% of KAN-susceptible (KAN(s)) specimens. Inclusion of the ahpC and eis promoter gene regions was critical for optimal test sensitivity for the detection of INH resistance in the Eastern Cape and KAN resistance in Moldova. (This study has been registered at ClinicalTrials.gov under registration number NCT02170441.).

Indexed as

Bacterial ProteinsCapreomycinDrug Resistance, Multiple, BacterialIsoniazidKanamycinMicrobial Sensitivity TestsMoldovaMutationMycobacterium tuberculosisRifampinSouth AfricaTuberculosisTuberculosis, Multidrug-ResistantBacterial ProteinsCapreomycinIsoniazidKanamycinRifampin

Identifiers

PMID27090176
PMCPMC4914621
OpenAlexW2338990134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.